Key Highlights
- $175M Series B financing led by RA Capital Management with broad investor participation.
- Funds to advance CPTX2309, Capstan’s lead in vivo CAR-T candidate, towards early clinical trials.
- Capstan aims to revolutionize autoimmune treatment with its targeted lipid nanoparticle (tLNP) technology.
Source: Business Wire
Notable Quotes
- “We are proud to support Capstan and their mission to lead in vivo CAR-T,” – Nandita Shangari, Ph.D., Managing Director at RA Capital Management
- “This Series B financing brings together an exceptional syndicate of investors that recognize the potential of Capstan’s in vivo CAR-T technology,” – Laura Shawver, Ph.D., President and Chief Executive Officer at Capstan
SoHC's Take
Capstan Therapeutics, Inc. has positioned itself at the forefront of biotechnological innovation with its recent Series B financing success. By securing $175M in an oversubscribed round, the company is well-equipped to push the boundaries of in vivo CAR-T therapy, starting with its promising candidate, CPTX2309. This effort underscores a strategic move towards addressing autoimmune disorders in a novel and potentially more efficacious manner. The significant backing by a diverse group of investors reflects confidence in Capstan’s technological platform and its potential to disrupt traditional therapeutic modalities. The biotech’s journey represents a pivotal moment in the pursuit of advancing RNA delivery technologies for reprogramming cells in vivo, setting a promising precedent for future developments in the field.
